<DOC>
	<DOCNO>NCT02002208</DOCNO>
	<brief_summary>The purpose study determine whether OC000459 reduce disease severity prevent flare people moderate severe atopic dermatitis ( AD ) .</brief_summary>
	<brief_title>Effect OC000459 Moderate Severe Atopic Dermatitis</brief_title>
	<detailed_description>The study include patient Th2 high eosinophilic phenotype typically severe disease prone flare .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Indoleacetic Acids</mesh_term>
	<criteria>1 . Atopic dermatitis define score least 9 Nottingham Eczema Severity Score , stratify moderate ( score 9 11 inclusive ) severe ( score 12 15 inclusive ) disease . 2 . Fully documented history use topical corticosteroid ( TCS ) and/or topical calcineurin inhibitor ( TCI ) . Subjects without fully document history exclude study . 3 . Male female subject moderate severe atopic dermatitis treat TCS and/or TCI ( without emollient ) time screen previous month . 4 . Subjects must least 1 AD flare previous 6 month . 1 . Receipt forbidden medication include counter preparation herbal medicine within 14 day first dose day exception paracetamol maximum 2g daily . 2 . Use systemic steroid within 4 week screen visit , light therapy immunosuppressant within 2 month screen visit . 3 . Use NSAIDs . 4 . Subjects initially diagnose AD age 2 year exclude unless either coexist history asthma and/or allergic rhinoconjunctivitis . 5 . Subjects contact dermatitis exclude . 6 . Subjects acute skin infection acute disease flare . Subjects active flare screen randomisation period ( visit 1 2 ) may manage accord normal clinical practice rescreened flare longer active .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>48 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>